Asia Pacific Oncology Based Molecular Diagnostics Market Size & Outlook
Asia Pacific oncology based molecular diagnostics market, 2018-2030 (US$M)
Related Markets
Asia Pacific oncology based molecular diagnostics market highlights
- The Asia Pacific oncology based molecular diagnostics market generated a revenue of USD 605.4 million in 2023.
- The market is expected to grow at a CAGR of 15.8% from 2024 to 2030.
- In terms of segment, instruments was the largest revenue generating product in 2023.
- Instruments is the most lucrative product segment registering the fastest growth during the forecast period.
Asia Pacific data book summary
| Market revenue in 2023 | USD 605.4 million |
| Market revenue in 2030 | USD 1,689.5 million |
| Growth rate | 15.8% (CAGR from 2023 to 2030) |
| Largest segment | Instruments |
| Fastest growing segment | Instruments |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Instruments |
| Key market players worldwide | Abbott Laboratories, Bayer AG, BD, Agilent Technologies Inc, Danaher Corp, Hologic Inc, Qiagen NV, Roche, Siemens AG, Sysmex Corp |
Other key industry trends
- In terms of revenue, Asia Pacific region accounted for 22.4% of the global oncology based molecular diagnostics market in 2023.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 1,689.5 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Oncology based Molecular Diagnostics Market Scope
Oncology based Molecular Diagnostics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Asia Pacific oncology based molecular diagnostics market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to oncology based molecular diagnostics market will help companies and investors design strategic landscapes.
Instruments was the largest segment with a revenue share of 100% in 2023. Horizon Databook has segmented the Asia Pacific oncology based molecular diagnostics market based on instruments covering the revenue growth of each sub-segment from 2018 to 2030.
Asia Pacific is expected to grow at the fastest CAGR of 19.1% during the forecast period. Increasing incidence of cancer in this region especially in the low- and middle-income countries can be attributed to large aging populations and changes in lifestyle associated with economic development and epidemiologic transition.
Furthermore, large variations in cancer incidence were observed especially in the populations in different sub-regions of Asia Pacific. High incidence of lung, breast, stomach, colorectal, prostate, and cervical cancers makes it difficult to control the incidence rate in the Asia Pacific region.
Presence of huge base of target population, growing establishment of healthcare, and high unmet clinical needs are anticipated to provide a potential growth platform in this region for key manufacturers.
Reasons to subscribe to Asia Pacific oncology based molecular diagnostics market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Asia Pacific oncology based molecular diagnostics market databook
-
Our clientele includes a mix of oncology based molecular diagnostics market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific oncology based molecular diagnostics market , including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific oncology based molecular diagnostics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Asia Pacific oncology based molecular diagnostics market
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
